Beijing: China has officially approved its first implantable brain-computer interface (BCI) device, marking a significant step forward in the country's efforts to compete with United States firms in the rapidly evolving field of neurotechnology. The announcement came from the National Medical Products Administration, the nation's drug regulator, signaling a new era in medical technology for patients suffering from partial paralysis due to spinal cord injuries.

According to Anadolu Agency, the approved device was developed by Neuracle Medical Technology and is specifically designed for adult patients with certain types of paralysis. Clinical trials demonstrated promising results, with patients using Neuracle's BCI showing enhanced abilities to grasp and hold objects with their hands. This breakthrough highlights the potential of BCI technologies to significantly improve the quality of life for individuals with severe physical impairments.

The approval of Neuracle's BCI device comes amidst a surge in the number of Chinese startups venturing into BCI technologies. These startups are positioning themselves as competitors to established players like Elon Musk's Neuralink, gaining traction through regulatory support and increased investments. The development reflects a broader trend of Chinese innovation in advanced technology sectors.

The approval news also had a positive impact on the stock market, particularly among companies associated with BCI technologies. Shares of Hong Kong-listed firms such as Sanbo Hospital Management Group, Innovation Medical Management, and Nanjing Panda Electronics experienced a significant rise, with each seeing an increase of over 10%. This stock rally underscores investor confidence in the future of BCI technologies and their potential market impact.